MedTech Europe in the headlines in April 2026

MedTech Europe in the headlines in April 2026

Posted on 07.05.2026

The recent media coverage showcased MedTech Europe's consistent role as a leading voice in European medical technology, spanning regulatory reforms, evolving geopolitical situations, and the launch of the breakthrough medical devices pilot program.

EU Data Act brings yet more questions for medtech

In Medtech Insight, MedTech Europe is hoping that the European Parliament addresses industry concerns around the EU Data Act in a similar way to recent AI Act amendments - but with parts of the Data Act already in effect, the sector finds itself on the backfoot.

EU negotiators were expected to conclude negotiations on the AI omnibus on 28 April, a file which hides a significant change for the medical devices sector. Currently, medical devices with an AI component have to meet both MDR and AI Act requirements. MedTech Europe's Alexander Olbrechts told POLITICO that this can lead to "duplication and then legal uncertainty in some cases, and long certification timelines, without adding any safety benefits."

MDR breakthrough medical device pilot begins

One of the EU's promised updates to the Medical Device Regulation (MDR) and In Vitro Diagnostic Regulation (IVDR) has entered its pilot phase as the European Medicines Agency (EMA) tests a new regulatory pathway for breakthrough medical devices. MedTech Europe said to Medtech Insight that the introduction of pathways for breakthrough innovation was "critical for more rapid access to needed, safe and effective technologies."

RAPS 2026 preview: EU medtech regulation at a crossroads

Updates to MDR, IVDR and the AI Act will be front of mind at this year's Regulatory Affairs Professionals Society conference in Lisbon, that MedTech Europe will be part of. In Medtech Insight, MedTech Europe is keen to see less burdensome versions of MDR and IVDR that improve the attractiveness of the EU market, and hopes that the updates can be implemented relatively quickly.

Medtech sector remains vigilant despite Middle East ceasefire

Commenting on geopolitical developments, MedTech Europe stressed the importance of continued vigilance despite announcements of a conditional ceasefire in the Middle East. In a written comment to POLITICO, we noted: "The recent announcement of a ceasefire, conditional on the strait's reopening, signals some ease on immediate pressure. However, until passage is restored in practice, the situation remains a moving target and warrants close monitoring." The statement underlined the sector's awareness of ongoing supply chain sensitivities and the need for stability to ensure uninterrupted access to medical technologies.

Medtech says EU-Australia deal misses mark

The European Commission signed its trade deal with Australia at the end of March, describing it as a "win-win on both sides". But industry group MedTech Europe told Euractiv the agreement "could have been more meaningful" for the sector. "Mutual recognition of conformity assessment for medical devices and in vitro diagnostics was not included in the scope of the deal, despite its clear benefits for patients and industry," said Diana Kanecka, the group's Director of International Affairs.

For more information, please contact , Manager Communications.